APA (7th ed.) Citation

Sanjay, P., Adam, J., Laura, C., Shobhit, B., Georgios, I., Carl, G., . . . Benjamin J., S. (2025). 258 HORIZON-01: A phase I–III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). Lung Cancer (01695002), 200, N.PAG. https://doi.org/10.1016/j.lungcan.2025.108367

Chicago Style (17th ed.) Citation

Sanjay, Popat, et al. "258 HORIZON-01: A Phase I–III Platform Study Evaluating the Efficacy and Safety of Multiple Therapies in Patients with Biomarker-defined Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)." Lung Cancer (01695002) 200 (2025): N.PAG. https://doi.org/10.1016/j.lungcan.2025.108367.

MLA (9th ed.) Citation

Sanjay, Popat, et al. "258 HORIZON-01: A Phase I–III Platform Study Evaluating the Efficacy and Safety of Multiple Therapies in Patients with Biomarker-defined Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)." Lung Cancer (01695002), vol. 200, 2025, p. N.PAG, https://doi.org/10.1016/j.lungcan.2025.108367.